Federal Grant Award Summary

Yale University received a $792,513 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 8, 2026, with a completion date of March 31, 2031. The project, "Serotype Re-emergence and Vaccine Impact in the Era of Next-Generation Pneumococcal Vaccines," will deliver mathematical and statistical modeling analyses to understand the mechanisms driving pneumococcal serotype dynamics and vaccine effectiveness patterns. The research will produce novel insights into serotype re-emergence drivers and differences in impact between pneumococcal conjugate vaccines (PCVs), with particular emphasis on evaluating how next-generation PCVs that target up to 31 serotypes compare to currently available vaccines.

The deliverables will include epidemiological models informed by newly collected colonization data linked with vaccination history, hypothesis testing through mathematical and statistical approaches, and predictive evaluations of serotype dynamics under different vaccination strategies. These research products are designed to inform evidence-based policy decisions regarding optimal pneumococcal vaccine selection and deployment strategies across different age groups and populations, addressing the substantial burden of pneumococcal disease that persists despite two decades of PCV usage in the United States.